Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline

Inventors

Cvetovich, Raymond • Warchol, Tadeusz

Assignees

Paratek Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8383610-B2

Patent

Publication Date

2013-02-26

Expiration Date


Abstract

Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.

Core Innovation

The invention describes crystalline forms of the tosylate salt of Compound 1, identified as 9-(2,2-dimethylpropyl-aminomethyl)-minocycline. It distinguishes three tosylate polymorphs by their X-ray powder diffraction patterns using Cu Kα radiation. The specified peak sets are approximately 8.06, 13.02, and 18.83° 2θ; approximately 5.11 and 15.60° 2θ; and approximately 11.88 and 16.12° 2θ.

Comparative XRPD patterns are provided for the three forms, including indexed diffraction peaks and comparisons involving recrystallized and temperature- or time-dependent samples. The crystalline tosylate demonstrates greater stability than the free base for weeks to months at room temperature. The background, abstract, and summary sections are omitted, so the specific problem being solved is not explicitly described in patent.

Claims Coverage

The supplied relevant claims identify one independent claim comprising three inventive features directed to distinct polymorphs of the tosylate salt of Compound 1 based on specified X-ray powder diffraction peak sets.

Polymorph characterized by peaks at approximately 8.06, 13.02, and 18.83° 2θ

A polymorph of the tosylate salt of Compound 1 characterized by an X-ray powder diffraction pattern including peaks at approximately 8.06, 13.02, and 18.83° 2θ using Cu Kα radiation.

Polymorph characterized by peaks at approximately 5.11 and 15.60° 2θ

A polymorph of the tosylate salt of Compound 1 characterized by an X-ray powder diffraction pattern including peaks at approximately 5.11 and 15.60° 2θ using Cu Kα radiation.

Polymorph characterized by peaks at approximately 11.88 and 16.12° 2θ

A polymorph of the tosylate salt of Compound 1 characterized by an X-ray powder diffraction pattern including peaks at approximately 11.88 and 16.12° 2θ using Cu Kα radiation.

The independent claim distinguishes three tosylate polymorphs of Compound 1 through their respective X-ray powder diffraction peak sets, with dependent claims directed to detailed diffraction signatures and a pharmaceutical composition.

Stated Advantages

The crystalline tosylate is reported as more stable than the free base, with stability for weeks to months at room temperature.

Documented Applications

Pharmaceutical compositions comprising a claimed polymorph and a pharmaceutically acceptable diluent, excipient, or carrier.

Therapeutic uses are described in the supplied partial content, but no specific use is provided.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.